about
ALS TDI
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective
therapeutics that stop ALS as soon as possible. Focused on meeting this urgent unmet medical
need, ALS TDI executes a robust discovery program, as well as a multi-pronged approach to
validate potential therapeutics; including small molecules, protein biologics, gene therapies
and cell-based constructs. The Institute's unique, industrial-scale platform allows for the
development and testing of dozens of potential therapeutics each year. Built by and for
patients, the Institute is the world's largest ALS research center and the only nonprofit
biotechnology company with more than 30 professional scientists focused on a single disease
indication. In addition, the Cambridge, Massachusetts based research Institute collaborates
with leaders in both academia and industry.
As a nonprofit, we rely on the generosity of the ALS Community. Those that give more than
$1,000 cumulative in a calendar year become members of the Leadership Giving Circle.
Learn more about giving and view the most recent membership listings.
ALS TDI is a proud partner of MDA
in the effort to develop effective treatments for ALS patients
today. In 2007, ALS TDI, MDA and its Augie's Quest initiative launched a historic fundraising partnership which brought $18 million to our
lab over the last three years. In addition to funding ALS TDI, MDA has been instrumental partners in the
development and execution of our research program, including working with us to gain access to and set up
relationships with several clinics around the country through which we collect samples for analysis. The MDA
is a key partner in our efforts and share our focus on delivering on our mission: effective treatments that
slow and stop this horrific disease.
what
WE DO
ALS TDI combines the passion and dedication of a nonprofit organization with the entrepreneurial
and scientific spirit of a biotechnology company
-
Our laboratory, the leading drug discovery program for ALS, bridges a critical research gap
-
Our in-house expertise translates research into potential drug candidates by screening drugs
in the SOD1 mouse model of ALS.
-
Our scientific collaborations are designed to bring the most promising leads closer to
patient use.
-
We share emerging knowledge on the disease with patients, physicians, and researchers as
quickly and comprehensively as possible.
-
Every decision is made in the interest of finding effective treatments for people living
with ALS.
-
Our unique approach accelerates drug development for ALS.
our
VISION
We envision a future where patients no longer die from ALS and where today's patients are
alive, well, and enjoying the company of their children and grandchildren.
We envision a future where treatments are developed for diseases based on their ability to
save and improve human lives, not their potential to make profit. In this future we
envision a Center where research science is re-connected to patients by bringing together
patients, doctors, and researchers to openly share their findings, knowledge, and insight,
and where that information is made available to the world. We envision a future where this
model has expanded and changed the healthcare system into one that strives and succeeds at
effectively seeking treatments for all diseases.